✨ Free AI Report
4basebio PLC: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research 4basebio PLC
Company Research

4basebio PLC: Business Overview, Financials & Competitive Analysis

4basebio PLC scores 7/10 on the AskCyborg Cyborg Score (Strong). Enabling synthetic DNA provider with validated pharma partnerships, positioned for growth in next-generation therapeutics with regulatory validation. Company has achieved critical regulatory milestones (FDA IND approval, MHRA GMP certification), secured major pharma partnerships, and completed significant capital raise. However, early-stage with negative cash flow and modest market cap of £85m.

What is 4basebio PLC's industry? 4basebio PLC (4basebio.com) operates in Synthetic Biology / Advanced Therapeutics Manufacturing. AskCyborg classifies 4basebio PLC under Synthetic Biology / Advanced Therapeutics Manufacturing in its company registry.

4basebio is a Cambridge-based biotechnology company pioneering synthetic DNA production through its proprietary enzymatic DNA synthesis platform, producing GMP-grade synthetic DNA and mRNA with superior speed, purity,...

7/ 10Strong

Cyborg Score thesis

Enabling synthetic DNA provider with validated pharma partnerships, positioned for growth in next-generation therapeutics with...

Read the full analyst-debate transcript →
Industry Synthetic Biology / Advanced Therapeutics Manufacturing
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest 4basebio PLC Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for 4basebio PLC

AskCyborg analysts argue the bull and bear cases for 4basebio PLC across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
4basebio PLC OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

4basebio PLC Overview

Pro stress-test →

4basebio is a Cambridge-based biotechnology company pioneering synthetic DNA production through its proprietary enzymatic DNA synthesis platform, producing GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability. The company offers application-specific DNA constructs tailored for gene therapies, genome editing, mRNA production, and DNA vaccines.

Strategic Profile

Pro stress-test →

Following FDA IND approval, a global Tier 1 pharmaceutical partner has begun dosing patients with an mRNA product developed using 4basebio's proprietary opDNA® template. Since completing a £40 million investment in November 2024, 4basebio achieved MHRA GMP certification in April 2025 for manufacture and supply of synthetic DNA for clinical use.

Competitive Landscape

Pro stress-test →

4basebio competes in the synthetic DNA and advanced therapeutics sector, addressing plasmid-based production limitations with enzymatic synthesis. Main competitors include Ginkgo Bioworks, Synthego, and other synthetic biology platforms, differentiated by GMP-grade manufacturing capability and pharma validation.

Industry Context

4basebio PLC operates in Synthetic Biology / Advanced Therapeutics Manufacturing.

Key facts

Founded: 2008 · Headquarters: Cambridge, UK · Employees: 101 · Market cap: £85.17m

What the analysts stress-tested

The top findings that survived the multi-agent debate for 4basebio PLC.

  • Tier 1 pharma partner now in Phase 1 clinical trials with opDNA-templated mRNA candidate
  • MHRA GMP certification (April 2025) de-risks manufacturing for clinical applications
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • April 2025Received MHRA GMP licence for manufacture and supply of synthetic DNA
  • November 2024Completed £40 million strategic investment
  • +2 moreTrack every material event for 4basebio PLC as it happens. Explore monitoring →
Get alerted when 4basebio PLC has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Synthetic DNA PlatformCell programming platform for bioengineering→CRISPR SynthesisGene editing and synthetic biology tools→Plasmid DNA ManufacturingTraditional plasmid-based DNA production→

Compare 4basebio PLC with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

4basebio PLC operates in Synthetic Biology / Advanced Therapeutics Manufacturing. See how the rest of the sector scores on the Cyborg framework.

Browse Synthetic Biology / Advanced Therapeutics Manufacturing research →
NEW · MCP server

Ask your AI assistant about 4basebio PLC

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare 4basebio PLC and its top competitor on Cyborg Score”
“What did 4basebio PLC do this quarter?”
“Is 4basebio PLC a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does 4basebio PLC do?+
4basebio is a Cambridge-based biotechnology company pioneering synthetic DNA production through its proprietary enzymatic DNA synthesis platform, producing GMP-grade synthetic DNA and mRNA with superior speed, purity,...
What is 4basebio PLC's Cyborg Score?+
4basebio PLC has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are 4basebio PLC's main competitors?+
Named competitors include Synthetic DNA Platform, CRISPR Synthesis, Plasmid DNA Manufacturing. The full competitive landscape is in the AskCyborg report.
How can I get the full 4basebio PLC research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the 4basebio PLC research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track 4basebio PLC over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Synthetic Biology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Genscript Biotech7Twist Bioscience Corporation4Ginkgo Bioworks Holdings, Inc.